| Autor: |
Medford HM; Graduate Program in Pharmaceutical Sciences, College of Pharmacy, Washington State University, Spokane, WA, USA., Marsh SA |
| Jazyk: |
angličtina |
| Zdroj: |
Future cardiology [Future Cardiol] 2014 Nov; Vol. 10 (6), pp. 801-12. |
| DOI: |
10.2217/fca.14.42 |
| Abstrakt: |
Heart failure treatment currently centers on symptom management, primarily through reductions in systemic blood pressure and fluid retention. The O-linked attachment of β-N-acetylglucosamine to cardiac proteins is increased in cardiovascular disease and heart failure, and O-GlcNAc transferase (OGT) is the enzyme that catalyzes this addition. Deletion of OGT is embryonically lethal, and cardiomyocyte-specific OGT knockdown causes the exacerbation of heart failure. Stem cell therapy is currently a major focus of heart failure research, and it was recently discovered that OGT is intricately involved with stem cell differentiation. This article focuses on the relationship of OGT with epigenetics and pluripotency, and integrates OGT with several emerging areas of heart failure research, including calcium signaling. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
